Výsledky vyhledávání - "Peter C. Pieslor"

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

Autor: Margaret von Mehren, Zev A. Wainberg, Mohamed Darif, Gerald R. Galluppi, Carolyn D. Britten, Sarah Harris, Wayne Saville, Roger B. Cohen, Stephen Leong, Artemios Vassos, Peter C Pieslor

Publikováno v: Investigational New Drugs

SummaryPurpose The IGF-1R signaling pathway has been implicated in multiple cancers as important for cell survival, proliferation, invasion and metastasis. BIIB022 is a non-glycosylated human IgG4 monoclonal antibody (mAb) with specificity for IGF-1R

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ace92cc60afa1d593af8ccd7fa35ba2
https://doi.org/10.1007/s10637-014-0064-y

Zobrazit plný text záznamu

Barriers to achieving commercial success for diagnostic and therapeutic radiopharmaceuticals

Autor: Peter C. Pieslor

Publikováno v: Nuclear medicine and biology. 34(7)

The concluding session of this workshop focused on barriers that might be impeding the successful transition of radiopharmaceuticals from research tools to diagnostics and therapeutics that reach commercial success. Some lessons can be learned by rev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b8df706ffce88037fe9b67ed017cc0
https://pubmed.ncbi.nlm.nih.gov/17921024

Zobrazit plný text záznamu

Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature

Autor: Charles Theuer, Stephen M. Ansell, Peter C. Pieslor, Christos Emmanouilides, Katie Vo, Thomas E. Witzig, Arturo Molina, Leo I. Gordon, Russell J. Schilder, Myron S. Czuczman

Publikováno v: Clinical lymphoma. 5(3)

Yttrium 90-labeled ibritumomab tiuxetan is approved for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL). To date, the efficacy of repeated courses of radioimmunoconjugate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de930b1b12e95dfe09066168ef9ccd30
https://pubmed.ncbi.nlm.nih.gov/15636698

Zobrazit plný text záznamu

AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo

Autor: Erick Gamelin, Steve Abella, Kathleen S. Keegan, Gloria Juan, Robert Radinsky, Justin N. Huard, Richard Kendall, Patricia McElroy, Gregory Friberg, Kam Cheung, William Wayne, Peter C Pieslor, Angela Coxon, Kelly Hanestad, Tammy L. Bush, Marc Payton, Mary K. Stanton

Publikováno v: Blood. 122:3823-3823

Aurora kinases A and B play essential roles in multiple stages of mitosis and are frequently overexpressed in a subset of human cancers, including acute myeloid leukemia (AML) (Ikezoe T et al, 2007). AMG 900, a potent and highly selective small molec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ad7356b5b097d57268dcd83a35962be
https://doi.org/10.1182/blood.v122.21.3823.3823

Zobrazit plný text záznamu

Splenic metastasis from colon carcinoma imaged using In-111 OncoScint

Autor: Christine A. White, Peter C. Pieslor, Robert R. Varney

Publikováno v: Clinical nuclear medicine. 20(6)

The In-111 OncoScint scan appearance of splenic metastasis from colon cancer is not well described. A case is presented in which a splenic metastasis had decreased tracer uptake on In-111 OncoScint imaging correlating with a new abnormality on a rest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a50c3eca42dadc097f7b685993cf5f9
https://pubmed.ncbi.nlm.nih.gov/7648747

Zobrazit plný text záznamu

Nonvisualized kidney on bone scintigraphy due to a depressed diaphragm

Autor: Robert P. Brouillard, Michael A. Noon, Peter C. Pieslor

Publikováno v: Clinical nuclear medicine. 19(9)

A 55-year-old woman with a 1-year history of nonsmall cell lung cancer underwent planar bone imaging with nonvisualization of the right kidney. The kidneys were in their usual location as seen on a bone scan taken 13 months earlier. Subsequent comput

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e09c2464a23944fc6e13837815f78790
https://pubmed.ncbi.nlm.nih.gov/7982329

Zobrazit plný text záznamu

Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors

Autor: D. R. Camidge, Mohamed Darif, Peter C Pieslor, M. von Mehren, Carolyn D. Britten, K. Balogh, Sarah Harris, K. Lear, Stephen Leong, Zev A. Wainberg

Publikováno v: Journal of Clinical Oncology. 28:2612-2612

2612 Background: The IGF pathway is believed to play a key role in the pathogenesis of several tumors. BIIB022 is a human, nonglycosylated IgG4 monoclonal antibody that binds to IGF-1R and blocks I...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::494fba8cbdd6c05c6c3fd3d49f886167
https://doi.org/10.1200/jco.2010.28.15_suppl.2612

Zobrazit plný text záznamu

Incidence of Altered Biodistribution Detected by Indium 111 (111In) Imaging Prior to Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy: Results from a Zevalin Imaging Registry

Autor: Gene Menendez, Christine A. White, Peter S. Conti, Jacqueline Aussie, P. Foster, Thomas Ryskamp, V. Douglas Harrough, Dan Matso, Peter C. Pieslor

Publikováno v: Blood. 104:4570-4570

Background: The yttrium 90 (90Y) ibritumomab tiuxetan (ZevalinÒ) therapeutic regimen consists of rituximab 250 mg/m2 on day 1 and 8, followed by indium 111 (111In) ibritumomab tiuxetan for imaging on Day 1 and 90Y ibritumomab tiuxetan for therapy o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d54a84e0719db210a78b417e3bad4560
https://doi.org/10.1182/blood.v104.11.4570.4570

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání